Market research
MYOV Myovant Sciences Ltd
NYSE USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 27
- Dividend yield
- 0.0%
- Beta
- 2.15
Profile
Company facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- USG637AM1021
- Market cap
- 3B
- P/E ratio
- Not available
- Analyst target
- 27
- Dividend yield
- 0.0%
- Beta
- 2.15
About
About Myovant Sciences Ltd
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MYOV discussion.
5 years, 4 months ago
Myovant Sciences Ltd is currently in a long term uptrend where the price is trading 1.5% above its 200 day moving average.
From a valuation standpoint, the stock is 96.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 51.3.
Myovant Sciences Ltd's total revenue rose by 132.4% to $1M since the same quarter in the previous year.
Its net income has increased by 13.7% to $-74M since the same quarter in the previous year.
Finally, its free cash flow grew by 955.4% to $574M since the same quarter in the previous year.
Based on the above factors, Myovant Sciences Ltd gets an overall score of 5/5.